A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.
Also called NCT01951235
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 315 participants
- Sponsor
- Poxel SA
- Registry
-
NCT01951235 -
2012-004045-33
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Latvia
- Registry status
- Completed
Technical summary
Registry record NCT01951235. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Imeglimin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Poxel SA
Record details
- Record id
cardio:ct-nct01951235- Content hash
ab10ac2fcc1cf4ff9e97f7ccac59868d2acc0be404ae0a8721f03038323045ff